SAR 566658

Drug Profile

SAR 566658

Alternative Names: huDS6-DM4; SAR-566658

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Developer ImmunoGen; Sanofi
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 30 May 2017 ImmunoGen and Sanofi amends a licensing agreement granting exclusive, fully-paid license of SAR 566658 to Sanofi
  • 07 Apr 2017 Sanofi completes a phase I trial in Solid tumours (second-line therapy or greater) in Spain, USA and France (IV) (NCT01156870)
  • 07 Dec 2016 Phase-II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (IV) (EudraCT2016-001962-27)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top